Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Paraneoplastic syndromes

S S Agarwala1

  • 1Division of Medical Oncology, University of Pittsburgh Medical Center, University of Pittsburgh Cancer Institute, Pennsylvania, USA.

The Medical Clinics of North America
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Melanoma: immunotherapeutic approaches.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2007
Same author

Histamine dihydrochloride: inhibiting oxidants and synergising IL-2-mediated immune activation in the tumour microenvironment.

Expert opinion on biological therapy·2001
Same author

Phase 1, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer.

Cytokines, cellular & molecular therapy·2001
Same journal

Care Transitions Continue to Evolve.

The Medical clinics of North America·2026
Same journal

Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

The Medical clinics of North America·2026
Same journal

Care Transitions and Value-Based Payment Models in the United States.

The Medical clinics of North America·2026
Same journal

Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

The Medical clinics of North America·2026
Same journal

Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

The Medical clinics of North America·2026
Same journal

Social Determinants of Health: Unique Considerations in Transitions of Care.

The Medical clinics of North America·2026
See all related articles

Paraneoplastic syndromes are cancer effects distant from the tumor. Recognizing these endocrine, nervous, hematologic, and dermatologic disorders aids cancer diagnosis and treatment.

Area of Science:

  • Oncology
  • Internal Medicine

Background:

  • Paraneoplastic syndromes are manifestations of cancer occurring distant from the primary tumor or its metastases.
  • These syndromes represent a complex interplay between the immune system and cancer, leading to systemic effects.

Purpose of the Study:

  • To discuss important paraneoplastic syndromes.
  • To highlight the diagnostic and therapeutic significance of recognizing these remote cancer effects.

Main Methods:

  • Review of literature on paraneoplastic syndromes.
  • Discussion of key syndromes affecting endocrine, nervous, hematologic, and dermatologic systems.

Main Results:

  • Paraneoplastic syndromes can involve multiple organ systems.

Related Experiment Videos

  • Early recognition is crucial for timely diagnosis and management of underlying malignancy.

    • Conclusions:

    • Paraneoplastic syndromes are critical indicators of underlying cancer.
    • Understanding these syndromes improves patient outcomes through integrated diagnostic and therapeutic strategies.